Sotorasib在NSCLC中的接下来是什么？
What's Next for Sotorasib in NSCLC?
发表日期：2023 Mar 17
作者：
来源：
Cancer Discovery
摘要：
CodeBreaK 200试验表明，与多西他赛相比，索托拉西布导致疾病进展或死亡的相对风险降低了34％，但整体生存率没有提高。尽管KRAS抑制剂成本高，但毒性较小可能会使其更具优势。亚组分析和组合试验正在进行中，以优化使用索托拉西布和其他KRAS抑制剂的治疗方案。 ©2023美国癌症研究协会。
The CodeBreaK 200 trial showed that sotorasib led to a 34% decrease in relative risk of disease progression or death compared with docetaxel but yielded no improvement in overall survival. Despite the KRAS inhibitor's high cost, less toxicity likely tips the balance in its favor. Subgroup analyses and combination trials are underway to optimize treatment with sotorasib and other KRAS inhibitors.©2023 American Association for Cancer Research.